

September 2026



GEORGIA SOCIETY OF CLINICAL ONCOLOGY



WHAT'S INSIDE

Pharmaceutical News & Highlights

What Oncologists,
Pharmacists, and Clinicians
Need to Know

GORDON

Hello & Welcome

As we enter the final quarter of 2026, the oncology pharmaceutical landscape continues to evolve with important advances in cancer therapeutics, precision medicine, and diagnostic technologies. Following a summer of significant scientific developments, attention is increasingly focused on translating emerging clinical evidence into meaningful improvements in patient care.

Antibody-drug conjugates (ADCs), bispecific antibodies, cellular therapies, and molecularly targeted treatments remain central to oncology innovation. Advances in next-generation sequencing (NGS), biomarker-driven treatment selection, and emerging diagnostic technologies continue to expand opportunities for personalized cancer care. At the same time, efforts to improve access to innovative therapies and precision medicine testing remain essential to ensuring that scientific progress translates into better outcomes for patients across diverse practice settings.

At GASCO, we are pleased to reflect on the success of our 2026 Annual Meeting & Best of ASCO®, held August 21–22 at The Hotel at Avalon in Alpharetta. The meeting brought together oncology professionals and industry colleagues from across Georgia for two days of scientific education, clinical updates, and meaningful collaboration. We extend our sincere appreciation to our faculty, attendees, and Corporate Partners for their contributions to this important educational event.

Looking ahead, preparations are well underway for the 2026 GASCO Fall Meeting: Advancing Hematology and Oncology Care, October 16–17 at the Grand Hyatt Atlanta Buckhead. The program will explore emerging developments in hematologic malignancies, precision oncology, and solid tumor treatment, with particular attention to the practical application of new evidence in clinical practice. We look forward to another opportunity to bring together Georgia's oncology community for education, discussion, and collaboration.

Please note that the Pharmaceutical News & Highlights newsletter will not be published in October, as the GASCO team will be dedicating its full attention to final preparations for the Fall Meeting. We look forward to resuming publication in November with continued coverage of important FDA approvals, clinical research, pharmaceutical industry developments, and news from GASCO's Corporate Partners.

Thank you to our readers for your continued engagement and to our community oncology practices and health system members for your dedication to patients throughout Georgia. We are especially grateful to our Corporate Partners for their ongoing support of oncology education, research, and innovation.

We look forward to welcoming you to our October Fall Meeting and continuing our shared commitment to advancing cancer care across Georgia.

GASCO Corporate Partner FDA Approvals for New Hematology/Oncology Drugs or New Indications

For A Complete List Visit:



**U.S. FOOD & DRUG
ADMINISTRATION**



[www.fda.gov/drugs/resources-information-approved-drugs/
oncology-cancerhematologic-malignancies-approval-
notifications?randparam=819615](https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications?randparam=819615)

In addition to posting this information for our Corporate Members in GASCO's pharmaceutical newsletter, the information is also posted on GASCO's website at:

www.gasco.us/fda-drug-approvals.php



On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.

[More Info >>](#)

GASCO Corporate Partner FDA Approvals for New Hematology/Oncology Drugs or New Indications

On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

[More Info >>](#)



On September 18, 2026, the Food and Drug Administration approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. Inluriyo and Verzenio are manufactured by Eli Lilly and Company.

[More Info >>](#)



On August 25, 2026, the Food and Drug Administration approved zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals)

- in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr (Tevimbra, BeOne Medicines USA, Inc.), as first-line treatment for adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test, and
- in combination with fluoropyrimidine-, and platinum-containing chemotherapy, as first-line treatment for adults with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test.: dolutegravir

[More Info >>](#)

[Jazz Pharmaceuticals Press Release >>](#)



GASCO Corporate Partner FDA Approvals for New Hematology/Oncology Drugs or New Indications



On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).

[More Info >>](#)

On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).

[More Info >>](#)



On June 24, 2026, the Food and Drug Administration approved an update to the prescribing information for Ibrance (palbociclib), adding a new indication for adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) locally advanced or metastatic breast cancer.

[Full prescribing information](#) including medication guide.



On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

[More Info >>](#)





REGENERON*

We aim to push the bounds of science to make

LIFE-CHANGING MEDICINES

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases.

Founded and led for over 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories. Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases.

Learn more at [Regeneron.com](https://www.regeneron.com) →

Follow @Regeneron



Oncology Trends to Watch

Developments in Precision Medicine, Therapeutics, and Technology

From Scientific Innovation to Clinical Implementation

As oncology enters the final quarter of 2026, recent FDA approvals and advances in molecular diagnostics are reinforcing the movement toward more individualized cancer treatment. Developments since late July highlight the growing importance of biomarker-directed therapies, earlier treatment intervention, novel immunotherapies, and more efficient approaches to cancer care.



Precision Oncology: New Approvals Expand Targeted Treatment

Recent FDA decisions underscore the expanding role of molecular testing in identifying appropriate treatment options.

- **Breast cancer:** September approvals of camizestrant and imlunestrant combinations introduce additional treatment options for patients with ESR1-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. The camizestrant approval is particularly noteworthy because it supports a treatment change based on molecular detection of an ESR1 mutation during ongoing therapy.
- **Lung cancer:** The September 9 accelerated approval of sevabertinib for HER2-mutated, locally advanced or metastatic nonsquamous non-small cell lung cancer adds another targeted treatment option for a molecularly defined patient population.
- **Pancreatic cancer:** The August 26 approval of daraxonrasib introduces a RAS-directed treatment option for certain patients with metastatic pancreatic adenocarcinoma.

Together, these developments reinforce the importance of timely molecular profiling and the integration of biomarker results into treatment decisions.

Oncology Trends to Watch

Developments in Precision Medicine, Therapeutics, and Technology

Liquid Biopsy Moves Toward Real-Time Treatment Guidance

Circulating tumor DNA (ctDNA) testing is becoming increasingly relevant beyond initial molecular profiling.

The September approval of camizestrant in combination with a CDK4/6 inhibitor highlights a treatment strategy in which an emerging ESR1 mutation can prompt a therapeutic change before radiographic disease progression.

This development illustrates the potential for blood-based molecular monitoring to support more responsive treatment decisions.

The broader oncology community continues to evaluate how liquid biopsy and MRD testing can inform treatment selection, monitor resistance, and identify recurrence. Clinical utility, appropriate testing intervals, and reimbursement remain important considerations.

Novel Immunotherapies Expand Treatment Possibilities

The August 6 accelerated approval of vusolimogene oderparepvec, an oncolytic viral therapy, in combination with nivolumab for certain patients with advanced melanoma represents another development in immunotherapy.

The treatment introduces an additional option for patients whose disease has progressed following PD-1-based therapy.

In hematologic malignancies, the August 13 accelerated approval of iberdomide in combination with daratumumab and dexamethasone for previously treated multiple myeloma reflects continued development of novel immune-modulating therapies.

These advances highlight the expanding diversity of immunotherapeutic approaches beyond conventional checkpoint inhibition.

Oncology Trends to Watch

Developments in Precision Medicine, Therapeutics, and Technology

Radioligand Therapy Advances Into Earlier Treatment Settings

Radiopharmaceuticals remain an important area of oncology innovation.

On July 31, the FDA approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) in combination with androgen receptor pathway inhibitor therapy for patients with PSMA-positive metastatic prostate cancer in the androgen pathway modulation-naïve or -sensitive setting.

This development illustrates the movement of radioligand therapy into earlier treatment settings and reinforces the importance of biomarker-directed patient selection.

As radiopharmaceutical programs expand, treatment capacity, specialized infrastructure, and multidisciplinary coordination will remain important considerations.



Multi-Cancer Early Detection Approaches a Regulatory Milestone

Multi-cancer early detection (MCED) testing remains an emerging area of oncology diagnostics.

In September, FDA review of GRAIL's Galleri blood test brought renewed attention to the potential role of blood-based technologies in detecting multiple cancer types.

The technology is intended to complement established cancer screening rather than replace recommended screening methods.

Important questions remain regarding clinical benefit, false-positive findings, follow-up diagnostic pathways, and insurance coverage.

The outcome of regulatory review and additional clinical evidence will be important developments to monitor.

Oncology Trends to Watch

Developments in Precision Medicine, Therapeutics, and Technology

Oncology Operations: A Shift Toward Simplified Treatment Authorization

Innovation in oncology extends beyond therapeutics and diagnostics.

In September, Aetna announced plans to simplify cancer treatment prior authorization beginning in 2027 by introducing a bundled authorization process for multiple components of oncology care.

The initiative is intended to reduce repetitive administrative requirements associated with treatment, imaging, and other services.

For oncology practices, the development highlights increasing attention to administrative efficiency, treatment access, and the operational burden associated with complex cancer care.

Looking Ahead: Fourth-Quarter 2026

The oncology community will be watching several developments as the year concludes:

- Additional clinical data from the October European Society for Medical Oncology (ESMO) Congress, particularly involving ADCs, targeted therapies, and immunotherapy combinations.
- Continued development of ctDNA-guided treatment strategies and MRD testing.
- Regulatory and clinical developments involving multi-cancer early detection.
- Further advances in personalized cancer vaccines and other novel immunotherapies.
- Expanded clinical applications of artificial intelligence in genomic interpretation, diagnostics, and oncology workflow.
- Continued attention to reimbursement, treatment access, and the integration of new technologies into community oncology practice.

The overarching trend: Oncology innovation is increasingly focused not only on developing new therapies, but also on identifying the appropriate patients, determining the optimal timing of treatment, and improving the delivery of increasingly complex cancer care.

**Just when you thought there
wasn't a sequel...**

**EXPLORE THE LATEST
FLAURA2 DATA**



**Learn more at
TagrissoHCP.com**



This product information is intended for US Healthcare Professionals only.
TAGRISSO is a registered trademark of the AstraZeneca group of companies.
©2026 AstraZeneca. All rights reserved. US-114189 7/26



What's Happening in Pharma

Rare inherited EGFR mutation linked to dramatically increased lung cancer risk

Dana-Farber Cancer Institute

Newsroom and Publications / New Releases and Announcements

September 17, 2026

A rare inherited mutation in the Epidermal Growth Factor Receptor (EGFR) gene is associated with a 25-fold increased risk of lung cancer, according to a study by investigators at Dana-Farber Cancer Institute and 23andMe Research Institute. The findings included de-identified, aggregated genetic data from more than 3.3 million 23andMe research-consented participants.

Among people who never smoked, carriers of the mutation were more than 60 times as likely to develop lung cancer as people without it. Researchers identified EGFR T790M as one of the strongest inherited risk factors for lung cancer discovered to date. This could have important implications for genetic testing and future lung cancer screening strategies for people who carry the mutation.

The findings were published in *Science*.

"Today, lung cancer screening is driven almost entirely by smoking history," says Jaclyn LoPiccolo, M.D., Ph.D., attending physician and lung cancer researcher at Dana-Farber Cancer Institute, who co-led the study. "Our findings raise the possibility that, in the future, screening could also be dictated by inherited genetic risk. If further studies confirm the benefit, people with EGFR T790M could be identified through genetic testing and offered personalized CT screening to identify lung cancers when they are at their most curable stage."

Although most lung cancers are associated with tobacco use or exposure, the proportion diagnosed in people who have never smoked has been rising. Yet the genetic factors underlying these cancers, particularly the role of inherited risk, aren't well understood.

[Full Article >>](#)

What's Happening in Pharma

Chemotherapy Drug Shortages Continue to Challenge Oncology Practices

American Society of Health-System Pharmacists | September 16, 2026

Shortages of essential chemotherapy medications remain an ongoing concern for oncology practices and hospital pharmacies.

Updated shortage reports indicate continued supply limitations affecting carboplatin and ifosfamide, with availability varying by manufacturer, formulation, and vial size.

For ifosfamide, Baxter reports manufacturing delays, while Hikma cites increased demand. Some formulations are expected to return to supply in late September or October 2026, although certain products remain available through other manufacturers.

The situation continues to highlight the importance of pharmaceutical supply-chain resilience, inventory management, and coordination between oncology practices, pharmacies, and manufacturers.

[ASHP: Ifosfamide Shortage Update >>](#) [ASHP: Carboplatin Shortage Update >>](#)



Approved in 5 indications¹

**OVER 290,000 PATIENTS TREATED
WITH BRUKINSA GLOBALLY*²**



*Based on March 2026 Symphony Claims/In-office Dispenses (IOD) data from GPO Networks/Internal Analysis.



SEE DATA FOR BRUKINSA

References: 1. BRUKINSA. Package insert. BeOne Medicines USA, Inc.; 2025.
2. Data on file. BeOne Medicines USA, Inc.

BRUKINSA and BeOne Medicines are trademarks owned by BeOne Medicines I GmbH or its affiliates.

© BeOne Medicines I GmbH, 2026 All Rights Reserved. 0522-BRU-PRC-038 6/2026

What's Happening in Pharma

Pharmaceutical Industry Weighs Future of U.S.–China Drug Licensing Agreements

Reuters | September 18, 2026

The U.S. Treasury Department is developing rules that could allow American pharmaceutical companies to continue licensing most drug candidates from Chinese biotechnology firms while restricting certain transactions involving sensitive biotechnology.

The proposed approach comes amid growing investment by U.S. pharmaceutical manufacturers in Chinese-developed medicines and increasing debate over national security, intellectual property, and the competitiveness of the domestic biotechnology industry.

Industry participants have expressed differing views. Some pharmaceutical companies support continued access to international drug innovation, while other stakeholders have called for tighter restrictions.

The rules remain under development and could influence future pharmaceutical licensing agreements, research partnerships, and global drug development strategies.

[Full Article – Reuters >>](#)



Corporate Partners Mergers & Acquisitions



AbbVie

AbbVie completes acquisition of Apogee Therapeutics

September 3, 2026 | Completed | Approximately \$10.9 billion

AbbVie completed its acquisition of Apogee Therapeutics for approximately \$10.9 billion, expanding its immunology pipeline with investigational therapies targeting inflammatory and immune-mediated diseases.

The acquisition adds zumilokibart, a long-acting monoclonal antibody targeting IL-13, which is being developed for atopic dermatitis. Apogee's pipeline also includes investigational therapies for asthma.

Although the acquisition is not oncology-focused, it represents a significant portfolio expansion for AbbVie.

[Full Press Release >>](#)



Ipsen

Ipsen completes acquisition of Kartos Therapeutics

August 21, 2026 | Completed | Up to \$1.75 billion

Ipsen completed its acquisition of Kartos Therapeutics, adding navtemadlin, an investigational oral MDM2 inhibitor in Phase III development for myelofibrosis.

Navtemadlin is being evaluated in combination with ruxolitinib for patients who have experienced a suboptimal response to standard treatment.

The transaction includes \$450 million in upfront consideration and up to \$1.3 billion in potential milestone payments. Top-line results from the Phase III POIESIS trial are expected in 2027.

The acquisition advances Ipsen's late-stage hematology and oncology pipeline.

[Full Press Release >>](#)

Corporate Partner Mergers & Acquisitions



Johnson & Johnson

Johnson & Johnson completes acquisition of Firefly Bio

September 3, 2026 | Completed | Approximately \$10.9 billion

Johnson & Johnson completed its \$1 billion cash acquisition of Firefly Bio, expanding its oncology pipeline with a novel degrader antibody conjugate (DAC) platform.

Firefly Bio's proprietary Firelink technology is designed to deliver protein-degrading agents directly to cancer cells. The acquisition strengthens Johnson & Johnson's efforts to develop targeted therapies for difficult-to-treat solid tumors, including cancers driven by KRAS mutations.

The technology represents an emerging approach to precision oncology that combines antibody-based targeting with targeted protein degradation.

[Full Press Release >>](#)

Reblozyl[®]

New data available

[Click here to learn more](#)

The reliability of structural variants. The speed of digital PCR.

Introducing **FoundationOne®MRD**
for early-stage breast cancer



SEE THE DIFFERENCE

SCAN TO LEARN MORE

FoundationOne MRD is performed by SAGA Diagnostics US, Inc. and has not been cleared or approved by the FDA.

News From Our Corporate Partners



AbbVie

AbbVie's bispecific T-cell engager shows promise on ph. 3 multiple myeloma trial

FIERCE Biotech

By Marissa Russo

Sep 3, 2026 9:20am

AbbVie released positive phase 3 data Thursday showing that its bispecific T-cell engager etentamig improved response rates and progression-free survival in patients with relapsed/refractory multiple myeloma.

The monthly dosing schedule demonstrated low rates of cytokine release syndrome (CRS) and fatal infections, with the potential to enable treatment in outpatient and community-based settings.

"The evolution of multiple myeloma has been one of going from a state of incurable disease, which for the large part it still is, to a place where now it's almost a chronic disease where patients are living longer," Daejin Abidoye, M.D., vice president and therapeutic area head, oncology, solid tumor and hematology at AbbVie, told Fierce. "Being able to improve upon therapies and therapeutic modalities today that allow patients not only to live longer but to live better, fuller lives, has become a focus for us."

[Full Article >>](#)

News From Our Corporate Partners



AstraZeneca

Enhertu demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

AstraZeneca
Media
14 September 2026

6-month improvement in median progression-free survival vs. pembrolizumab plus chemotherapy

AstraZeneca and Daiichi Sankyo's Enhertu is the first HER2-directed therapy to delay disease progression over standard of care in a Phase III trial in this setting.

Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as a 1st-line treatment of patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous non-small cell lung cancer (NSCLC).

Results were presented today during the Presidential Symposium at the IASLC 2026 World Conference on Lung Cancer (#WCLC26) hosted by the International Association for the Study of Lung Cancer in Seoul, South Korea (abstract #PL03.08).

News From Our Corporate Partners



AstraZeneca

Enhertu demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial (cont.)

In the primary endpoint of PFS, Enhertu monotherapy significantly reduced the risk of disease progression or death by 37.0% versus pembrolizumab plus chemotherapy (hazard ratio [HR] 0.63; 95% confidence interval [CI] 0.50-0.79; $p < 0.0001$). Median PFS was 14.3 months with Enhertu compared to 8.3 months for pembrolizumab plus chemotherapy as assessed by blinded independent central review (BICR). A favourable PFS trend was seen for Enhertu across key subgroups, including the prespecified stratification factors of brain metastases, liver metastases, smoking status, HER2 mutation status (exon 19 or exon 20), and de novo or recurrent disease.

[Full Article >>](#)

News From Our Corporate Partners



BioNTech

BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout

FIERCE Biotech | By Nick Paul Taylor | Sep 14, 2026 4:15am

BioNTech has linked gotistobart to a median overall survival (OS) of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.

The data come from Preserve-003, a two-stage phase 3 trial comparing gotistobart to docetaxel in metastatic squamous non-small cell lung cancer (sqNSCLC) patients without actionable genomic alterations. Checkpoint inhibitors work in the first-line population, but the chemotherapy docetaxel, with or without the VEGFR2 antibody ramucirumab, is still the standard of care for patients who relapse.

[Full Press Release >>](#)



Boehringer Ingelheim

Boehringer, Envisagenics sign \$1B multi-target oncology collaboration

FIERCE Biotech | By Will Maddox | Sep 22, 2026 8:00am

Boehringer Ingelheim and AI drug discovery company Envisagenics have agreed to a potential \$1 billion multi-year pact that will task Boehringer with validating tumor-specific targets.

The German biopharma is interested in leveraging New York-based Envisagenics' artificial intelligence platform, SpliceCore, which focuses on RNA splicing. Though Envisagenics didn't share further payment details, co-founder and CEO Maria Pineda, Ph.D., told Fierce the upfront and milestone payments will be used to take its lead internal CNS candidate into the clinic.

[Full Press Release >>](#)

News From Our Corporate Partners



Caris Life Sciences

Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer

Caris Life Sciences | Release Details / News & Events / News Releases
August 27, 2026

Caris AI Insights for pancreatic cancer is proprietary, only available to Caris Life Sciences customers and not achievable through small panels

IRVING, Texas, Aug. 27, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced the publication of a study in npj Precision Oncology describing the development and validation of an AI-driven approach to optimize first-line treatment selection in pancreatic cancer, advancing a more personalized care path for one of the deadliest malignancies.

The study demonstrates the performance of Caris AI Insights™ to predict first-line treatment benefit using an AI-based molecular signature. In the testing cohort, standard molecular risk patients predicted to benefit from FOLFIRINOX achieved substantially longer median overall survival when treated with FOLFIRINOX rather than gemcitabine plus nab-paclitaxel (gem/nab-p) (16.0 vs 9.9 months). Approximately half of the patients in the study received a different first-line therapy than the model would have recommended, highlighting the potential opportunity for more biologically informed treatment selection to improve survival and reduce toxicity.

The Caris AI Insights signature for pancreatic cancer is included in the Caris Molecular Tumor Board Report. This report, built using whole exome sequencing (WES) and whole transcriptome sequencing (WTS) data, is available upon request at no additional cost when ordering MI Cancer Seek®. Caris AI Insights deliver clinically relevant findings across all tumor types, with disease-specific algorithms to support treatment decision-making in colon, breast, ovarian, pancreatic and lung cancer.

[Full Press Release >>](#)

News From Our Corporate Partners

GSK



GSK pens \$1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset

FIERCE Biotech | By Ben Adams | Sep 3, 2026 7:45am

GSK is handing over \$110 million upfront to Hutchmed in a deal worth up to \$1.295 billion to get its hands on a first-in-class oncology med.

That asset is HMPL-A830, a preclinical KRAS-EGFR-antibody conjugate slated to enter trials later this year.

The deal gives the British Big Pharma worldwide rights to develop and sell the therapy—but excludes Mainland China, Hong Kong, Macau and Taiwan.

[Full Article >>](#)

A NEW TREATMENT OPTION FOR 1L mTNBC

SCAN THE QR CODE TO
EXPLORE THE NEW DATA



News From Our Corporate Partners



GSK

GSK prepares frontline FDA bid for Jideytro, its first lung cancer drug

FIERCE Pharma | By Angus Liu | Sep 13, 2026 7:00pm

GSK is advancing its inaugural lung cancer asset, Jideytro, toward a landmark first-line FDA approval, aided by an unprecedented complete response rate.

In a quick return for GSK's \$10.6 billion acquisition of Nuvalent, an early FDA nod in July has made Jideytro GSK's first commercial lung cancer drug, with a label covering advanced ROS1-positive non-small cell lung cancer following treatment with a prior ROS1 tyrosine kinase inhibitor (TKI). Now, the company is gunning for an expansion into the TKI-naïve population.

[Full Article >>](#)

GSK doubles down on Chimagen with \$750M multiple myeloma wager GSK doubles down on Chimagen with \$750M multiple myeloma wager

FIERCE Biotech | By Nick Paul Taylor | Sep 15, 2026 7:15 am

GSK has bet up to \$750 million on a Chimagen Biosciences trispecific T-cell engager (TCE), positioning the Big Pharma to start phase 1 development of the multiple myeloma drug candidate next year.

The deal comes two years after GSK paid China's Chimagen \$300 million upfront for a trispecific lupus prospect. Neither party has disclosed the targets of the new candidate, but GSK shed some light on the rationale for the trispecific design.

TCEs have shown "transformational efficacy in multiple myeloma but have been associated with difficult tolerability profiles," GSK said. Chimagen designed its candidate to overcome the limitations of existing TCEs by targeting two tumor-associated antigens while also binding to T cells.

[Full Article >>](#)

News From Our Corporate Partners



Legend Biotech

Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

Legend Biotech
Press Releases
Sep 15, 2026

Ingrid Zhang, an accomplished global biopharmaceutical leader, joins Legend Biotech following a comprehensive Board-led search process

BRIDGEWATER, N.J.,
Sept. 15, 2026 (GLOBE NEWSWIRE)
-- Legend Biotech Corporation (NASDAQ: LEGN)

("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that its Board of Directors has appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026. Ingrid Zhang succeeds Alan Bash, who has served as Interim Chief Executive Officer since July 2026 and will resume his role as President, CARVYKTI.

[Full Press Release >>](#)

News From Our Corporate Partners



Novartis

Novartis inks \$3.2B subcutaneous drug delivery deal with Alteogen

FIERCE Biotech
By Nick Paul Taylor
Sep 2, 2026 7:51am

Novartis has struck a deal worth up to \$3.2 billion to work with Alteogen on subcutaneous drug delivery, joining Biogen and GSK on the list of drugmakers to pay to access the technology this year.

Korea's Alteogen has emerged as a major player in the subcutaneous drug delivery space in recent years. Competing with Halozyme Therapeutics, Alteogen has landed deals with leading drugmakers based on its rival approach to facilitating subcutaneous delivery. Merck & Co. handed Alteogen a big win in 2020 by picking its ALT-B4 technology for the subcutaneous version of Keytruda.

Since then, the Korean biopharma company has expanded its star-studded roster of clients. Novartis joined the list on Wednesday, entering into an option and license agreement for ALT-B4. The Swiss drugmaker has multiple options to obtain exclusive rights to develop drugs using the delivery technology. Novartis didn't respond immediately to Fierce Biotech's request for more information about the alliance.

[Full Press Release >>](#)

News From Our Corporate Partners

Taiho Oncology

Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer



FIERCE Biotech
By Marissa Russo
Sep 13, 2026 9:45pm

Cullinan Therapeutics and Taiho Oncology have unveiled phase 3 data for their tyrosine kinase inhibitor (TKI) that could challenge Johnson & Johnson's Rybrevant for patients with advanced non-small cell lung cancer (NSCLC) in the front-line setting.

Adding zipalertinib to platinum-based chemotherapy improved survival by six months in patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutation-positive NSCLC. The results, presented on Monday at the World Conference on Lung Cancer in Seoul, were part of a planned interim analysis. The partners revealed that the phase 3 study hit its primary endpoint for progression-free survival (PFS) last month, but had been holding back the detailed data.

The Rezilient3 trial enrolled 279 adults with previously untreated, locally advanced or metastatic NSCLC with the relevant mutations. In the study, a combination of zipalertinib and chemotherapy achieved a statistically significant median PFS of 14.5 months, compared to 8.5 months in patients on chemotherapy alone.

[Full Article >>](#)



Patient Support at Your *Fingertips*



**Arm your patients with support
and resources as they navigate
treatment with a Genmab medication**

MyNavCare Patient Support by Genmab®
offers services to assist your patients on
their treatment journey.



To enroll patients, visit [MyNavCare.com](https://www.mynavcare.com)
For more information, call 1-866-NAV-CAR1 (1-866-628-2271).

*Based on eligibility requirements and Terms and Conditions.

†MyNavCare Patient Engagement Liaisons are part of the MyNavCare Patient Support by Genmab Program and do not provide medical advice or work under the direction of the prescribing healthcare providers. They are trained to direct patients to speak with their HCP about any treatment-related questions. MyNavCare Patient Support by Genmab is a trademark of Genmab A/S. © 2025 Genmab A/S. All rights reserved.

10/2025 COM-US-UNB-0000885

Education and Learning Resources

HOPA Guidelines, Standards & Clinical Resources



The **Hematology/Oncology Pharmacy Association (HOPA)** is the leading professional organization dedicated to advancing the practice of hematology and oncology pharmacy through education, clinical practice resources, research, advocacy, and professional development. HOPA's Guidelines, Standards, and Summaries resource library is an excellent reference for oncology pharmacists, pharmacy technicians, and other members of the cancer care team seeking evidence-based tools to support safe, high-quality patient care.

Among the resources available are:

- The **2026 Scope of Oncology Pharmacy Practice**, outlining the evolving role and competencies of oncology pharmacists.
- **ASHP-HOPA Oncology Pharmacy Technician Guidelines** for ambulatory oncology practice.
- Best practice standards for **oral oncolytic therapy, investigational drug services, and dose rounding of biologic and cytotoxic anticancer agents**.
- Curated links to key national and international clinical guidelines, including **NCCN, CPIC pharmacogenomics guidelines**, and immunotherapy toxicity management resources.
- Practical summaries and reference materials to support oral chemotherapy management, pharmacy operations, and quality improvement initiatives.

Explore the complete HOPA Guidelines, Standards & Summaries library:

[HOPA Guidelines, Standards & Summaries](#)

This resource is highly recommended for oncology pharmacists, pharmacy technicians, pharmacy residents, and multidisciplinary oncology teams looking for current practice guidance and implementation tools.

Education and Learning Resources

HOPA Expands Oncology Pharmacy Education for 2026

The **Hematology/Oncology Pharmacy Association (HOPA)** has expanded its educational offerings with new on-demand programs designed to help oncology pharmacists and other healthcare professionals stay current with evolving treatment approaches, clinical practice standards, and patient care.

HOPA's 2026 educational resources include:

- BCOP Self-Study Program: Released August 18, featuring literature-based learning and up to 17.5 continuing education credits.
- BCOP Sprint: A September 11 on-demand release offering focused education on emerging oncology treatment topics.
- BCOP Preparation and Recertification Courses: Scheduled for release September 30, providing structured education for oncology pharmacists pursuing or maintaining board certification.

These programs complement HOPA's existing clinical guidelines and practice resources and provide additional opportunities for professional development.

Precision Medicine Added to HOPA's Core Competency Program

HOPA's updated 2026 Core Competency Program offers self-paced educational modules for pharmacists and other healthcare professionals seeking foundational knowledge in oncology pharmacy.

The program includes 14 modules covering chemotherapy safety, treatment monitoring, supportive care, medication management, and reimbursement. New and updated content addresses oral anticancer agents, oncology precision medicine, and hazardous drug handling requirements.

The program offers up to 17.25 continuing education hours, with individual modules or a complete bundle available for purchase. Its precision medicine component provides a timely educational resource for oncology professionals navigating biomarker-directed treatment and increasingly complex therapeutic decisions.

[**Explore the Core Competency Program >>**](#)

Thank You to Our Generous Corporate Partners





THERE IS STRENGTH IN UNITY

**What we can do together
makes a difference in
advancing cancer care**

770-951-1018 | 3330 Cumberland Blvd • Suite 650 • Atlanta, GA 30339 | www.gasco.us

Thank you

GASCO is a highly respected and effective organization representing the greater cancer care community in Georgia.